Buyer's Remorse or Crocodile Tears? Big Pharma and the Health Care Reform Headwind
This article was originally published in RPM Report
Executive Summary
Here are how some Big Pharma companies described the impact of health care reform during their year-end earnings calls.
You may also be interested in...
Job One for Big Pharma: Repositioning in DC Post-Health Care Reform
How Wall Street’s reaction to the impact of health care reform may help the pharmaceutical industry make sure it pays off in the long run.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Cost-Based Pricing: The Real Threat Hiding In Latest US Drug Price Headlines
Bernie Sanders is back at it, getting headlines for demanding immediate price cuts to Novo’s blockbuster GLP-1 brands. But behind the familiar rhetoric is a newer threat: academic research on cost-based pricing that could one day feed into the emerging Medicare ‘negotiation’ system.